Electromagnetic pulses significantly decrease pain and inflammation associated with osteoarthritis of the knee, according to Henry Ford Hospital researchers…
NICE Asks For More Data On New Drug For Rheumatoid Arthritis
NICE’s independent appraisal committee has asked Roche, the manufacturer of tocilizumab (RoActemra), a new treatment for moderate to severe active rheumatoid arthritis, for further additional information on its product…
New ‘Work Charter’ Launched To Help 6.5m People With Musculoskeletal Conditions To Stay In Work, UK
Today the Arthritis and Musculoskeletal Alliance (ARMA), backed by leading policymakers and employers, is calling for positive action to ensure people with musculoskeletal disorders (MSDs) are properly supported to access employment and remain in their jobs…
NICE Reassessment Of Switching Decision Brings Little Hope For Rheumatoid Arthritis Patients
The National Rheumatoid Arthritis Society (NRAS) has expressed their frustration at NICE’s provisional decision not to allow patients with rheumatoid arthritis to routinely switch from one Anti-TNF drug to another. This is the second time NICE has appraised the sequential effectiveness of multiple biologic therapies following NRAS’s successful appeal of negative NICE guidance on switching in 2007…
NICE Consults On Draft Recommendations For Treating Rheumatoid Arthritis After Treatment With A TNF Inhibitor Has Failed
The National Institute for Health and Clinical Excellence (NICE) is currently appraising a number of drugs as possible treatments for rheumatoid arthritis after treatment with a tumour necrosis factor (TNF) inhibitor has failed. This is a part review of NICE technology appraisal guidance 36, and a review of NICE technology appraisal guidance 126 and 141…
Rheumatologists Have Plenty Of Choice Among Biologic Agents For RA – Where Will Actemra Find Its Niche?
BioTrends Research Group released topline findings from LaunchTrends®: ACTEMRA, Wave 1, highlighting the market uptake of the product at one month post launch. Actemra (tocilizumab), marketed by Roche-Genentech, is a new IL-6 inhibitor with monthly dosing by IV infusion. The study results are based on an on-line survey completed by 77 rheumatologists in late February…
